Page last updated: 2024-11-13

jwh-210

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone: a cannabimimetic; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID45270396
CHEMBL ID549603
CHEBI ID186515
SCHEMBL ID6325541
MeSH IDM0586355

Synonyms (27)

Synonym
CHEMBL549603 ,
jwh-210
jwh182
824959-81-1
(4-ethylnaphthalen-1-yl)-(1-pentylindol-3-yl)methanone
CHEBI:186515
(4-ethylnaphthalen-1-yl)(1-pentyl-1h-indol-3-yl)methanone
AKOS015951328
4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone
unii-7h0xw15con
r18jyo04py ,
unii-r18jyo04py
bdbm50414058
FT-0673612
methanone, (4-ethyl-1-naphthalenyl)(1-pentyl-1h-indol-3-yl)-
j2.929.916a ,
CCG-208740
SCHEMBL6325541
1-pentyl-3-(4-ethyl-1-napthoyl)indole
LACIUQLUNACUKC-UHFFFAOYSA-N
(4-ethyl-1-naphthalenyl)(1-pentyl-1h-indol-3-yl)-methanone
jwh-210 ((4-ethylnaphthalen-1-yl)(1-pentylindol-3-yl)methanone) 0.1 mg/ml in acetonitrile
jwh-210 ((4-ethylnaphthalen-1-yl)(1-pentylindol-3-yl)methanone) 1.0 mg/ml in acetonitrile
jwh-210; (4-ethylnaphthalen-1-yl)(1-pentylindol-3-yl)methanone; (4-ethyl-1-naphthalenyl)(1-pentyl-1h-indol-3-yl)methanone
Q4041748
DTXSID301010019
jwh 210

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Acute adverse effects of JWH-210 typically include central nervous system depression or cerebral seizures, but also signs of sympathomimetic toxicity."( Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project.
Angerer, V; Auwärter, V; Eyer, F; Franz, F; Hermanns-Clausen, M; Kithinji, J; Spehl, M, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" Thus, controlled human pharmacokinetic (PK) studies are not allowed, although being relevant for interpretation of analytical results in cases of misuse or poisoning."( Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology.
Ewald, AH; Kettner, M; Laschke, MW; Lehr, T; Maurer, HH; Menger, MD; Schaefer, N; Schlote, J; Schmidt, PH; Wojtyniak, JG, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolecarboxamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cannabinoid receptor 2 Homo sapiens (human)Ki0.00070.00000.415610.0000AID419195
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID419197Selectivity ratio of pKi for human cloned CB2 receptor to pKi for CB1 receptor in rat brain2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID419195Displacement of [3H]CP-55940 from human cloned CB2 receptor by filtration assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID419196Selectivity ratio of pKi for CB1 receptor in rat brain to pKi for human cloned CB2 receptor2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID419194Displacement of [3H]CP-55940 from CB1 receptor in rat brain by filtration assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (4.55)29.6817
2010's17 (77.27)24.3611
2020's4 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]